Protocol summary
-
Study aim
-
Determination of effect of 8 weeks intervention with lavender-bergamot aroma, mindfulness counseling, aroma-mindfulness counseling on sexual function score, anxiety score, and levels of some serum bio-markers in postmenopausal women compared to control group
-
Design
-
A randomized controlled clinical trial with a factorial design, stratified by menopause duration. 132 postmenopausal women randomly will be divided into four groups of counseling based on mindfulness and aroma placebo, aromatherapy and routine care, counseling based on mindfulness and aromatherapy, and control group using Random Allocation Software (RAS) with 1:1:1:1 ratio.
-
Settings and conduct
-
Eligible women will be selected among health centers and randomly assigned into one of the four groups after giving written informed consent. Aroma and its similar placebo, 3 times daily, 2-3 drops on the skin for 8 weeks and counseling in 45-60 minutes sessions, once a week for 8 consecutive weeks will be administered.The blinding of researcher and participants in terms of counseling will not be possible
-
Participants/Inclusion and exclusion criteria
-
Inclusion criteria: Married postmenopausal women; Age between 50-60; Having records in Tabriz Elderly Friendly Centers; Mild to moderate anxiety; Sexual dysfunction score less than 28; PSQI 5 or more; Greene between 15-42.
Exclusion criteria: Use of herbal compounds to increase libido in men or women; Sensitivity to any of the herbal remedies; Occurrence of the adverse event within 3 months prior to the study;
-
Intervention groups
-
The groups receiving counseling based on mindfulness and aromatherapy, aromatherapy and routine care, counseling based on mindfulness and aromatherapy, or control group (placebo of aroma and routine care)
-
Main outcome variables
-
Mean score of sexual function after intervention
Mean score of anxiety after intervention
Serum level of some bio-markers after intervention
General information
-
Reason for update
-
Hi,
]t is hereby conveyed that due to the coincidence of the implementation stages of this trial with the corona pandemic and its various peaks, the sampling process was prolonged and sampling was completed with a delay on 2020-11-21 instead of 2020-03-15. Therefore, we want to correct the completion date of sampling. Also, along with the studied variables, due to the importance of sleep quality and menopausal symptoms in menopausal women, these two variables were also considered as a secondary outcome along with other variables. Therefore, please agree with the above amendments.
Thank you
-
Acronym
-
-
IRCT registration information
-
IRCT registration number:
IRCT20131009014957N8
Registration date:
2019-12-04, 1398/09/13
Registration timing:
registered_while_recruiting
Last update:
2021-07-05, 1400/04/14
Update count:
2
-
Registration date
-
2019-12-04, 1398/09/13
-
Registrant information
-
-
Recruitment status
-
Recruitment complete
-
Funding source
-
-
Expected recruitment start date
-
2019-11-22, 1398/09/01
-
Expected recruitment end date
-
2020-11-21, 1399/09/01
-
Actual recruitment start date
-
empty
-
Actual recruitment end date
-
empty
-
Trial completion date
-
empty
-
Scientific title
-
Effect of aromatherapy with essential oil of lavender-bergamot, and counseling based on mindfulness on sexual function, anxiety, and serum level of some bio-markers in postmenopausal women: A randomized controlled trial with factorial design.
-
Public title
-
Effect of aromatherapy and counseling based on mindfulness on sexual function, anxiety, and serum level of some bio-markers in postmenopausal women
-
Purpose
-
Supportive
-
Inclusion/Exclusion criteria
-
Inclusion criteria:
Willingness to participate in the study
Postmenopausal women between the ages of 50-60
Having read and write literacy
The Female Sexual Function Score less than 28
Having mild to moderate anxiety based on Beck Anxiety Scale
Having sex in the family limit with her permanent spouse
Having only one wife for the man
Natural menopause
Obtaining a score of 15-42 on the Greene scale
Having a score of 5 and higher in The Pittsburgh Sleep Quality Index (PSQI)
Exclusion criteria:
Known physical and mental illnesses based on person's self statement (depression, diabetes, cardiovascular disease, olfactory sensations, mental disability, diabetes)
Drugs affecting sex (sildenafil, antidepressants, antihistamines, diazepines, barbiturates, amphetamines, antihypertensive drugs, cocaine, thiazide diuretics, narcotics
Use of herbal ingredients to increase sexual desire in men or women (ginseng, cinnamon, ginger, etc.) and alergy to any herbal medicine
Addiction to the habitual consumption of alcohol and tobacco by women
Participate in other similar studies
Occurrence of an misadventure within 3 months prior of study (death or acute illness of close relatives)
Disorder in the sense of smell according to person's self and other nasal disorders (fracture, aberration, rhinitis)
Use of hormotherapy at last 6 month
-
Age
-
From 50 years old to 60 years old
-
Gender
-
Female
-
Phase
-
3
-
Groups that have been masked
-
- Outcome assessor
- Data analyser
-
Sample size
-
Target sample size:
132
-
Randomization (investigator's opinion)
-
Randomized
-
Randomization description
-
Postmenopausal women aged 50-60 years will be divided into four groups of aromatherapy and routine care, counseling based on Mindfulness-Based Intervention (MBI) and aromatherapy, counseling based on MBI and placebo of aromatherapy, and control group (placebo of aromatherapy and routine care) using the RAS software with four and eight blocks with a 1: 1: 1: 1 allocation ratio and will be stratified based on menopausal years (less than or greater than 5 years). To conceal the allocated intervention, type of counseling intervention (counseling or routine care) will be written on papers and along with allocated aromas or placebo will be placed in the matte and sealed envelopes numbered from 1 to 132 based on random sequence generated by a non-researcher. The first envelope will be given to the first eligible person and will be continued until the completion of sampling.
The participant, researcher and statistical analyst will not be aware of the contents of the package (allocation concealment). In this study, after the random allocation of the individual to the study group, the researcher and participant blindness would not be possible in terms of counseling,
-
Blinding (investigator's opinion)
-
Double blinded
-
Blinding description
-
In this study, outcome assessor and statistical analyst will be kept blind to the specific study groups. So that the combined aroma and its placebo will be poured into identical dark containers and identified only by random code of study. The outcome assessor and the statistical analyst will not be present at the consultation sessions. Questionnaires will not specify the type of intervention and only random code will be written. Also in the statistical software, only the code of the participants and the group number will be written.
-
Placebo
-
Used
-
Assignment
-
Factorial
-
Other design features
-
Ethics committees
1
-
Ethics committee
-
-
Approval date
-
2019-10-14, 1398/07/22
-
Ethics committee reference number
-
IR.TBZMED.REC.1398.749
Health conditions studied
1
-
Description of health condition studied
-
Anxiety
-
ICD-10 code
-
F41
-
ICD-10 code description
-
Other anxiety disorders
2
-
Description of health condition studied
-
Sexual dysfunction
-
ICD-10 code
-
F52
-
ICD-10 code description
-
Sexual dysfunction not due to a substance or known physiological condition
3
-
Description of health condition studied
-
Depression
-
ICD-10 code
-
F32
-
ICD-10 code description
-
Major depressive disorder, single episode
4
-
Description of health condition studied
-
Serum levels of some bio-markers
-
ICD-10 code
-
-
ICD-10 code description
-
5
-
Description of health condition studied
-
Menopausal symptoms
-
ICD-10 code
-
N95
-
ICD-10 code description
-
Menopausal and other perimenopausal disorders
6
-
Description of health condition studied
-
Sleep quality
-
ICD-10 code
-
G47
-
ICD-10 code description
-
Sleep disorders
Primary outcomes
1
-
Description
-
Anxiety score in Beck Anxiety Inventory
-
Timepoint
-
At baseline and 8 weeks after intervention
-
Method of measurement
-
Beck Anxiety Inventory
2
-
Description
-
Sexual function score in Female Sexual Function Index
-
Timepoint
-
At baseline and 8 weeks after intervention
-
Method of measurement
-
Female Sexual Function Index
3
-
Description
-
Serum level of cortisol
-
Timepoint
-
At baseline and immediately after intervention
-
Method of measurement
-
Elisa method by ELISA kits
Secondary outcomes
1
-
Description
-
Depression score using Beck Depression Inventory
-
Timepoint
-
At baseline and 8 weeks after intervention
-
Method of measurement
-
Beck Depression Inventory
2
-
Description
-
Serum level of malondialdehyde
-
Timepoint
-
َAt baseline and immediately after intervention
-
Method of measurement
-
By spectrophotometric method based on reaction with thiobarbituric acid
3
-
Description
-
Serum level of high-sensitivity C-Reactive Protein
-
Timepoint
-
َAt baseline and immediately after intervention
-
Method of measurement
-
Complex-based turbidometry based on the reaction between high-sensitivity C-Reactive Protein and specific antiserum
4
-
Description
-
Serum level of Total Antioxidant Capacity
-
Timepoint
-
َAt baseline and immediately after intervention
-
Method of measurement
-
By Autoanalyzer Abbott (Alcyon 300) using Randox kit
5
-
Description
-
Frequency of adverse events
-
Timepoint
-
While intervention
-
Method of measurement
-
Adverse events checklist
6
-
Description
-
Menopausal symptom score using Greene climacteric scale
-
Timepoint
-
At baseline and 8 weeks after intervention
-
Method of measurement
-
Greene Climacteric Scale
7
-
Description
-
The score of Pittsburgh Sleep Quality Index (PSQI)
-
Timepoint
-
At baseline and 8 weeks after intervention
-
Method of measurement
-
Pittsburgh Sleep Quality Index (PSQI)
Intervention groups
1
-
Description
-
Intervention group 1: Mindfulness consulting along with placebo of aroma. Mindfulness in-person counseling will be held once per week for eight weeks through the 45-60 minute sessions in a native language. The number of participants in each meeting will be at least eight and up to twelve. The last 15 minutes will be devoted to question and answer. Aroma placebo (probylene glycol) will be rubbed 2 to 3 drops, 2-3 times a day for 8 weeks. The placebo will be made by Goldaru Pharmaceutical Company and packed in 30 ml dark glass.
-
Category
-
Treatment - Other
2
-
Description
-
Intervention group 2: ََAromatherapy with essential oil of lavender-bergamot along with routine care. Lavender-bergamot essential oil will be applied 3 times daily, 2-3 drops each time for 8 weeks on the forearm. The composition of the essential oils will be in the form of 5% lavender and 0.4% bergamot essential oils. The pure essential oils will be provided by the Goldaru Pharmaceutical Company. The analysis of essential oils, blending of them with the desired concentration will be carried out in the Faculty of Pharmacy and will be packed in 30 ml dark glass.Routine care will be carried out in accordance with the Ministry's approved protocol.
-
Category
-
Treatment - Other
3
-
Description
-
Intervention group 3: Aromatherapy with essential oil of lavender-bergamot along with Mindfulness consulting. Lavender-bergamot essential oil will be applied 3 times daily, 2-3 drops each time for 8 weeks on the forearm. The composition of the essential oils will be in the form of 5% lavender and 0.4% bergamot essential oils. The pure essential oils will be provided by the Goldaru Pharmaceutical Company. The analysis of essential oils, blending of them with the desired concentration will be carried out in the Faculty of Pharmacy and will be packed in 30 ml dark glass. Mindfulness in-person counseling will be held once per week for eight weeks through the 45-60 minute sessions in a native language. The number of participants in each meeting will be at least eight and up to twelve. The last 15 minutes will be devoted to question and answer.
-
Category
-
Treatment - Other
4
-
Description
-
Control group: Placebo of aroma along with routine care. Aroma placebo (probylene glycol) will be rubbed 2 to 3 drops, 2-3 times a day for 8 weeks. The placebo will be made by Goldaru Pharmaceutical Company and packed in 30 ml dark glass. Routine care will be carried out in accordance with the Ministry's approved protocol.
-
Category
-
Placebo
1
-
Sponsor
-
-
Grant name
-
-
Grant code / Reference number
-
-
Is the source of funding the same sponsor organization/entity?
-
Yes
-
Title of funding source
-
Tabriz University of Medical Sciences
-
Proportion provided by this source
-
100
-
Public or private sector
-
Public
-
Domestic or foreign origin
-
Domestic
-
Category of foreign source of funding
-
empty
-
Country of origin
-
-
Type of organization providing the funding
-
Academic
Sharing plan
-
Deidentified Individual Participant Data Set (IPD)
-
Yes - There is a plan to make this available
-
Study Protocol
-
Undecided - It is not yet known if there will be a plan to make this available
-
Statistical Analysis Plan
-
Undecided - It is not yet known if there will be a plan to make this available
-
Informed Consent Form
-
Yes - There is a plan to make this available
-
Clinical Study Report
-
Yes - There is a plan to make this available
-
Analytic Code
-
Undecided - It is not yet known if there will be a plan to make this available
-
Data Dictionary
-
Undecided - It is not yet known if there will be a plan to make this available
-
Title and more details about the data/document
-
Requested data will be provided to researchers for statistical analysis of the submitted proposal (meta-analysis).
-
When the data will become available and for how long
-
ُStarting immediately after publication
-
To whom data/document is available
-
Data will be available to researchers as well as to journals
-
Under which criteria data/document could be used
-
The data will be available to researchers upon request and submission of a proposal to perform meta-analysis using IPD data after being unidentified. Also, in exceptional cases, data will be made available to journals for checking
-
From where data/document is obtainable
-
Refer to the email address (farshbafa@tbzmed.ac.ir)
-
What processes are involved for a request to access data/document
-
The requests will be sent by email and data will be available within a week
-
Comments
-